Multi-provincial Cohort for Hypertension (MUCH)
Study Details
Study Description
Brief Summary
The purpose of this study is to construct hypertension specialized cohort using uniform standards and specifications. This study timely collected multi-dimensional clinical information through electronic medical records, mobile health, data integration, informatics and computer modern techniques, linking self-reported data and big data platforms from different sources to timely obtain the incidence and mortality data, and integrating hypertension cohort samples and the associated clinical records systematically, in order to build a 30-thousand hypertension specialized cohort with fine phenotypic data and blood/urine samples, thus far to provide support for the development of precise medicine research and related industries.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Hospital based hypertension cohort
|
Drug: Antihypertensive Agents
Single or combination therapy with five type of antihypertensive agents, such as Ca channel blockers, ACE inhibitors, ARBs, diuretics, or beta-blockers.
Other: Cardiovascular risk factors
Different level of cardiovascular risk factors associated with genetics, environments and lifestyles.
|
| Community based hypertension cohort
|
Drug: Antihypertensive Agents
Single or combination therapy with five type of antihypertensive agents, such as Ca channel blockers, ACE inhibitors, ARBs, diuretics, or beta-blockers.
Other: Cardiovascular risk factors
Different level of cardiovascular risk factors associated with genetics, environments and lifestyles.
|
Outcome Measures
Primary Outcome Measures
- Composite end point of major cardiovascular and cerebrovascular events [From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year]
Composite end point of major cardiovascular and cerebrovascular events
Secondary Outcome Measures
- New-onset of cardiovascular events [From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year]
New-onset of cardiovascular events
- New-onset of stroke [From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year]
New-onset of stroke
- Total death [From date of enrollment until date of death from all cause, assessed up to 3 year]
Total death
- Major bleeding [From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year]
Major bleeding
- Atrial fibrillation [From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year]
Atrial fibrillation
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Clinical diagnosis of hypertension
-
over 18 years old
-
ti sign the informed consent
Exclusion Criteria:
-
with life-threatening severe disease, such as severe tumor or AIDs
-
pregnancy or lactating women,or plan to pregnant within half a year,
-
with severe mental disorders
-
participating in clinical trials
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Beijing Anzhen Hospital | Beijing | China | ||
| 2 | Beijing Tiantan Hospital | Beijing | China | ||
| 3 | Beijing Tsinghua Chang Gung Hospital | Beijing | China | ||
| 4 | Southwest Hospital, China | Chongqing | China | ||
| 5 | Nanfang Hospital of Southern Medical University | Guangzhou | China | ||
| 6 | Ruijin Hospital | Shanghai | China |
Sponsors and Collaborators
- Beijing Institute of Heart, Lung and Blood Vessel Diseases
- Beijing Tsinghua Chang Gung Hospital
- Beijing Tiantan Hospital
- Ruijin Hospital
- Nanfang Hospital of Southern Medical University
- Southwest Hospital, China
Investigators
- Principal Investigator: Jing Liu, MD,PhD, Beijing Institute of Heart, Lung and Blood Vessel Diseases
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2016YFC0900902